Head and neck cancer ranks as the seventh most common malignancy worldwide and remains a significant global public health challenge [1, 2]. Among these tumors, head and neck squamous cell carcinoma (HNSCC) accounts for more than 90% of cases [1]. In 2022, approximately 758,000 new cases were reported globally, underscoring the substantial disease burden associated with HNSCC [3]. Despite advances in multimodal treatment strategies, the overall 5-year survival rate remains unsatisfactory and is markedly lower in advanced stages and low-income regions [4–6]. These limitations highlight the urgent need for more effective therapeutic approaches and improved strategies for precise patient stratification [7–9].

In recent years, immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis, has emerged as a promising treatment modality for HNSCC [10–12]. Anti-PD-1 agents were approved by major regulatory agencies, including the Food and Drug Administration and the European Commission [13]. However, clinical responses remain limited, with relatively low objective response rates observed for agents such as pembrolizumab [14]. This variability in therapeutic efficacy underscores the critical need for reliable predictive biomarkers to optimize patient selection and improve treatment outcomes. Currently, PD-L1 expression, assessed by immunohistochemistry and quantified using the combined positive score (CPS), serves as the primary biomarker guiding immunotherapy decisions in clinical practice [15]. However, CPS evaluation is associated with several intrinsic limitations. The assessment is semi-quantitative and highly dependent on pathologist expertise, resulting in considerable variability, particularly in borderline cases. Furthermore, intratumoral heterogeneity and sampling bias further compromise the reproducibility and robustness of PD-L1 evaluation [12, 16, 17]. Collectively, these challenges limit the clinical utility of CPS and emphasize the need for more objective, standardized, and scalable assessment methods [18].

Artificial intelligence (AI), particularly deep learning-based computational pathology, has demonstrated considerable potential in extracting high-dimensional features from hematoxylin and eosin (H&E)-stained whole-slide images (WSIs) [19–22]. Recent studies suggest that AI models can infer molecular characteristics and tumor microenvironment features directly from routine histopathological images, offering a convenient and cost-effective alternative to conventional assays [23–25]. However, there remains a lack of clinically adopted AI-based tools for the assessment of PD‑L1 expression.

In this study, we developed an AI-based framework that integrates deep learning and machine learning to predict PD-L1 expression from H&E-stained slides in HNSCC. Tile-level features were extracted using a convolutional neural network and subsequently aggregated into slide-level representations through multi-feature fusion strategies. The model was validated in both internal and external cohorts, and its prognostic value was further assessed. Our results demonstrate that this AI-driven approach achieves robust predictive performance and may serve as a valuable tool to assist pathologists in PD-L1 evaluation, thereby supporting precision immunotherapy in HNSCC.

In the present study, we developed and validated a computational pathology framework that enables prediction of PD-L1 expression directly from routine H&E-stained WSIs in HNSCC. By integrating deep learning-derived morphological representations with machine learning-based feature aggregation, the proposed system achieved robust predictive performance across both internal and external cohorts. Importantly, our findings further demonstrate that AI-inferred PD-L1 status is not only technically feasible but also clinically informative, as evidenced by its ability to stratify patient survival. These results position AI-assisted histopathological analysis as a promising surrogate approach for molecular biomarker assessment in precision oncology, as has been shown in previous studies [24, 29–37].

A key clinical challenge addressed by this study is the limited reproducibility of PD-L1 CPS evaluation. Consistent with prior reports [38, 39], we observed only fair interobserver agreement among pathologists, with substantial variability particularly between less and more experienced observers. This highlights the intrinsic subjectivity and complexity of CPS scoring, which requires simultaneous evaluation of tumor and immune compartments within heterogeneous tissue architecture [11, 13–15, 17, 40]. From a clinical standpoint, such variability may directly impact therapeutic decision-making, especially in borderline cases where CPS thresholds determine eligibility for ICIs [38, 39]. The AI-based approach proposed here offers a standardized and reproducible alternative, potentially reducing observer-dependent bias and improving consistency in PD-L1 assessment across institutions.

Beyond reproducibility, our study contributes to the growing body of evidence that morphological features captured in H&E images encode latent molecular and immunological information [24, 37]. Although PD-L1 expression is conventionally assessed by immunohistochemistry, our results suggest that tumor architecture, stromal composition, and immune cell distribution patterns may collectively reflect underlying immune checkpoint activity. The relatively modest performance of the tile-level deep learning model indicates that local features alone are insufficient to capture this complexity. In contrast, the substantial improvement observed after WSI-level feature integration (AUC up to 0.900 in validation and 0.851 in testing) underscores the importance of global spatial context and multi-feature fusion. This aligns with emerging paradigms in computational pathology emphasizing hierarchical modeling and spatially aware feature aggregation [21, 22, 41].

From a methodological perspective, the dual-pipeline design combined with ensemble machine learning represents a flexible and scalable strategy for translating tile-level predictions into clinically meaningful outputs. Among the evaluated algorithms, LR demonstrated optimal performance, suggesting that, despite the complexity of upstream feature extraction, the final decision boundary may remain linearly separable in high-dimensional feature space. This finding has practical implications, as simpler models may offer advantages in interpretability, computational efficiency, and clinical deployment. Importantly, this study extends the utility of AI beyond biomarker prediction to prognostic stratification. By leveraging predicted PD-L1 probabilities, several models effectively distinguished patients with significantly different overall survival outcomes. This observation reinforces the biological relevance of PD-L1-associated immune states in HNSCC progression and supports the concept that AI-derived surrogate biomarkers may capture prognostically meaningful tumor-immune interactions [23, 29, 42]. Clinically, such models could complement existing staging systems by providing additional risk stratification, thereby informing postoperative surveillance and adjuvant treatment strategies.

From a translational perspective, the proposed framework offers several potential advantages. First, it utilizes routinely available H&E slides, eliminating the need for additional staining, reducing cost, and preserving tissue. Second, it enables retrospective analysis of archived specimens, facilitating large-scale studies and real-world validation. Third, it provides rapid and automated assessment, which may be particularly valuable in resource-limited settings where access to standardized immunohistochemistry and expert pathology review is constrained. Collectively, these features support the integration of AI-based tools into clinical workflows as decision-support systems rather than replacements for pathologists.

Nevertheless, several challenges remain before clinical implementation. The biological interpretability of AI models is still limited, and the specific morphological correlates of PD-L1 expression inferred by the model warrant further investigation using explainable AI techniques. Additionally, while our model demonstrated strong performance across two centers, broader validation in multi-center, multi-platform datasets is essential to ensure generalizability, as variability in tissue processing, staining protocols, and scanner characteristics may affect model robustness; standardization efforts and domain adaptation techniques will be critical for real-world deployment. Furthermore, independent validation by external research groups is essential to confirm the reproducibility, robustness, and clinical applicability of the framework across diverse patient populations and practice settings. Finally, prospective clinical trials are needed to determine whether AI-assisted PD-L1 assessment can improve patient selection for immunotherapy and ultimately translate into better clinical outcomes. Importantly, the current study focused exclusively on predicting PD-L1 positivity using a threshold of CPS ≥ 1, which represents a clinically relevant but relatively inclusive cutoff. Future studies should extend this framework to predict higher thresholds, particularly CPS ≥ 20, which are increasingly used to guide immunotherapy decision-making and may provide additional prognostic and therapeutic value. Incorporating multiple clinically meaningful PD-L1 cutoffs into AI-based prediction models may further enhance their utility for precision oncology and patient stratification.

In summary, we developed a robust AI-based computational pathology framework capable of predicting PD-L1 expression directly from H&E-stained slides in HNSCC. The model demonstrated strong performance across independent cohorts and showed potential in prognostic stratification. This approach provides a convenient, reproducible, and scalable alternative to conventional immunohistochemical assessment and may serve as a valuable adjunct tool for guiding immunotherapy and personalized clinical decision-making in HNSCC.